ATS 2026 Exhibitor: AI Lung Analysis Workflow Platform by Coreline
Coreline Soft will participate in ATS 2026 (American Thoracic Society International Conference) as an exhibitor (Booth No.1050), presenting its AI-powered lung analysis workflow platform for pulmonary disease assessment and treatment planning.
ATS 2026, held from May 15–20 in Orlando, brings together global experts across pulmonary, critical care, and sleep medicine, along with companies in medical devices, pharmaceuticals, and digital health.
Within this ecosystem, AI-powered imaging is emerging as a key component of clinical workflow and disease management infrastructure.
From Image Analysis to Clinical Workflow
Coreline’s AI platform goes beyond standalone CAD tools by integrating multiple layers of lung analysis into a unified workflow:
• Insight overlay for disease pattern visualization
• Quantitative measurement of lung structures
• Multi-parameter analysis across CT datasets
• Longitudinal tracking for disease progression
This enables clinicians to move from simple image interpretation to data-driven clinical decision-making.
AI for Lung Disease Assessment
Coreline’s platform supports comprehensive analysis across major pulmonary diseases:
• Chronic obstructive pulmonary disease (COPD)
• Interstitial lung disease (ILD)
• Lung cancer
Through AI-based quantitative analysis, clinicians can achieve:
• Objective and reproducible measurements
• Standardized interpretation across institutions
• Improved diagnostic confidence
Supporting BLVR with Quantitative Imaging
At ATS 2026, Coreline highlights the role of AI in Bronchoscopic Lung Volume Reduction (BLVR) planning.
BLVR requires precise imaging-based evaluation, including:
• Emphysema distribution
• Fissure completeness
• Target lobe identification
Coreline’s AI platform integrates these measurements into a structured workflow, enabling more accurate treatment planning.
Clinical Validation and Real-World Integration
Coreline collaborates with leading institutions such as Temple University Hospital, supporting:
• Clinical validation of imaging biomarkers
• Integration into real-world clinical workflows
• Research in advanced pulmonary interventions
This reflects a broader trend at ATS:
AI must be clinically validated and operationally integrated to deliver real value.
AI in the ATS Ecosystem
While ATS is not a technology-focused conference, AI is increasingly embedded across:
• Lung cancer screening
• COPD and ILD management
• Longitudinal disease monitoring
AI is evolving from a diagnostic aid into a core infrastructure for pulmonary care workflows.
Meet Coreline Soft at Booth No.1050 at ATS 2026 to explore AI-driven lung analysis workflows in action.
